
Moleculin Reports First Quarter 2025 Financial Results And Provides Corporate Update
(MENAFN- GlobeNewsWire - Nasdaq) Enrollment and dosing underway in Phase 3 clinical trial (the“MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML Regulatory and site selection progress to date supports interim data readout …